CN117616022A - 晶形 - Google Patents

晶形 Download PDF

Info

Publication number
CN117616022A
CN117616022A CN202280048877.0A CN202280048877A CN117616022A CN 117616022 A CN117616022 A CN 117616022A CN 202280048877 A CN202280048877 A CN 202280048877A CN 117616022 A CN117616022 A CN 117616022A
Authority
CN
China
Prior art keywords
dimethyl
phenylbutan
oxo
piperidin
piperidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280048877.0A
Other languages
English (en)
Chinese (zh)
Inventor
青山英幸
沼田豊治
须藤正树
岩田康弘
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Raqualia Pharma Inc
Original Assignee
Raqualia Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Raqualia Pharma Inc filed Critical Raqualia Pharma Inc
Publication of CN117616022A publication Critical patent/CN117616022A/zh
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
CN202280048877.0A 2021-07-30 2022-08-01 晶形 Pending CN117616022A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163227692P 2021-07-30 2021-07-30
US63/227,692 2021-07-30
PCT/JP2022/029430 WO2023008585A1 (en) 2021-07-30 2022-08-01 Crystalline forms

Publications (1)

Publication Number Publication Date
CN117616022A true CN117616022A (zh) 2024-02-27

Family

ID=85087024

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280048877.0A Pending CN117616022A (zh) 2021-07-30 2022-08-01 晶形

Country Status (10)

Country Link
US (1) US12552776B2 (https=)
EP (1) EP4377309A4 (https=)
JP (1) JP7765130B2 (https=)
KR (1) KR20240042400A (https=)
CN (1) CN117616022A (https=)
BR (1) BR112023025271A2 (https=)
CA (1) CA3223173A1 (https=)
MX (1) MX2024000903A (https=)
TW (1) TW202321216A (https=)
WO (1) WO2023008585A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12605394B2 (en) 2024-07-25 2026-04-21 Visionary Assets, Llc Compositions containing cannabinoid nanoparticles

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2600510C (en) 2005-03-11 2010-11-02 Pfizer Inc. Crystal forms of an imidazole derivative
KR101575703B1 (ko) * 2009-02-27 2015-12-10 라퀄리아 파마 인코포레이티드 모틸린 수용체에 대해 작용제 활성을 가진 옥시인돌 유도체
WO2012157288A1 (en) 2011-05-18 2012-11-22 Raqualia Pharma Inc. Polymorph form of 4-{[4-({[4-(2,2,2-trifluoroethoxy)-1,2-benzisoxazol-3-yl]oxy}methyl)piperidin-1-yl]methyl}-tetrahydro-2h-pyran-4-carboxylic acid
UY34094A (es) 2011-05-27 2013-01-03 Novartis Ag Derivados de la piperidina 3-espirocíclica como agonistas de receptores de la ghrelina
CA2867043A1 (en) 2012-05-03 2013-11-07 Novartis Ag L-malate salt of 2,7-diaza-spiro[4.5]dec-7-yle derivatives and crystalline forms thereof as ghrelin receptor agonists
CA2944982C (en) 2014-05-20 2022-06-07 Raqualia Pharma Inc. Benzisoxazole derivative salt

Also Published As

Publication number Publication date
BR112023025271A2 (pt) 2024-02-27
EP4377309A1 (en) 2024-06-05
EP4377309A4 (en) 2025-06-25
JP7765130B2 (ja) 2025-11-06
JP2024526952A (ja) 2024-07-19
TW202321216A (zh) 2023-06-01
US20240351998A1 (en) 2024-10-24
KR20240042400A (ko) 2024-04-02
US12552776B2 (en) 2026-02-17
CA3223173A1 (en) 2023-02-02
WO2023008585A1 (en) 2023-02-02
MX2024000903A (es) 2024-02-06

Similar Documents

Publication Publication Date Title
CN103702995B (zh) 4-{[4-({[4-(2,2,2-三氟乙氧基)-1,2-苯并异噁唑-3-基]氧}甲基)哌啶-1-基]甲基}-四氢-2h-吡喃-4-羧酸的多晶型形式
TWI610929B (zh) 多形體形式
HK1251553A1 (zh) 苯并异恶唑衍生物盐
CN117616022A (zh) 晶形
CN105164129B (zh) 多晶型物形式
HK40101847A (zh) 晶形
CN121712762A (zh) 氮杂螺衍生物盐
HK1216312B (en) Polymorph forms
HK1195066B (en) Polymorph form of 4-{[4-({[4-(2,2,2-trifluoroethoxy)-1,2-benzisoxazol-3-yl]oxy}methyl)piperidin-1-yl]methyl}-tetrahydro-2h-pyran-4-carboxylic acid
HK1231483B (en) Benzisoxazole derivative salt

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40101847

Country of ref document: HK

SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination